A reliable AI workflow needs to preserve context: brand versus molecule : Ozempic and Wegovy are both semaglutide, but not the same market object single versus dual agonist : tirzepatide is not simply another semaglutide brand indication : diabetes, obesity, and cardiovascular risk reduction are different analytic frames funding status : PBS and private-pay populations can behave very differently time period : a 2023 shortage-period record is not equivalent to a 2026 post-shortage record source type : TGA, PBS, PBAC, company releases, media reporting, and clinical trials have different evidentiary roles The main AI risk is not that a model cannot summarise GLP-1 information
The program covers using these drugs to maintain weight loss, and your provider can attest that you met the BMI criteria at the time you first started therapy, even if that was before July 2026.participation, and whether you meet the eligibility requirements
Your body, your results
One article outlined 25-30% of a 1600 kcal diet, which works out to 100-120 g/day of nutritional protein (Sievenpiper et al 2026)
doi:10.1016/j.heares.2009.06.009 92
